A twenty year perspective on melanoma therapy

Melanoma had long been considered to be particularly addressable with immunotherapy, but that reputation was built on modestly effective cytokine‐based immunotherapy. CTLA‐4 antibody therapy reinforced this legacy, but PD‐1 antibodies transformed the melanoma treatment landscape and lead the way for...

Full description

Saved in:
Bibliographic Details
Published in:Pigment cell and melanoma research Vol. 36; no. 6; pp. 563 - 575
Main Author: Flaherty, Keith T.
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01.11.2023
Subjects:
Antibodies
Cancer
Combined Modality Therapy
Cytokines
Humans
Immunotherapy
Melanoma
Melanoma - drug therapy
Melanoma - genetics
Proto-Oncogene Proteins B-raf - genetics
Therapy
ISSN:1755-1471, 1755-148X, 1755-148X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma had long been considered to be particularly addressable with immunotherapy, but that reputation was built on modestly effective cytokine‐based immunotherapy. CTLA‐4 antibody therapy reinforced this legacy, but PD‐1 antibodies transformed the melanoma treatment landscape and lead the way for immunotherapy to become standard treatment for more than half of the advanced cancer population. BRAF mutations were discovered in 8% of all cancer and nearly 50% of melanomas. Successful development of BRAF inhibitors and BRAF/MEK combination therapy in melanoma preceded regulatory approval across all cancer types. No cancer type saw outcomes improved by the same margin as melanoma in the decade of the 2010s. The rapid pace of progress seen from 2010 to 2014 has been followed by fewer treatments advances and smaller impact. Resistance to BRAF/MEK combination therapy and immune checkpoint antibody therapy remains to be addressed. Translational research insights suggest that new classes of therapy will be needed to make to next quantum step in patient outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1755-1471
1755-148X
1755-148X
DOI:10.1111/pcmr.13125